{
  "meta": {
    "title": "24_National_Health_Programmes_Ii_-_Nlep_Ntep_Naco",
    "url": "https://brainandscalpel.vercel.app/24-national-health-programmes-ii-nlep-ntep-naco-21dc4383.html",
    "scrapedAt": "2025-11-30T12:26:57.982Z"
  },
  "questions": [
    {
      "text": "Identify the organization that has the given emblem:",
      "choices": [
        {
          "id": 1,
          "text": "National Vector Borne Disease Control Programme"
        },
        {
          "id": 2,
          "text": "National Leprosy Eradication Programme"
        },
        {
          "id": 3,
          "text": "Integrated Child Development Scheme"
        },
        {
          "id": 4,
          "text": "National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Disease, and Stroke"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given image is the emblem of <strong>National Leprosy Eradication Programme (NLEP).</strong></p>\n<p><strong>Characteristics of NLEP emblem:</strong></p>\n<ul>\n<li>The <strong>lotus</strong> in the&nbsp;NLEP emblem<strong>&nbsp;</strong>symbolizes beauty and purity.</li>\n<li>A&nbsp;<strong>partially affected thumb,</strong>&nbsp;a&nbsp;<strong>normal forefinger,</strong>&nbsp;and the&nbsp;<strong>shape of a house </strong>symbolize that leprosy can be cured and a patient with leprosy can be a useful member of the society.</li>\n<li>The&nbsp;<strong>rising</strong>&nbsp;<strong>sun</strong> symbolizes hope and optimism.</li>\n<li>The emblem captures the spirit of hope and positivity in the eradication of leprosy.</li>\n</ul>\n<p>NLEP is a centrally sponsored health scheme of the Ministry of Health and Family Welfare, Govt. of India.</p><p>Option A:&nbsp;National Vector Borne Disease Control Programme (NVBDCP)</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a6ac9ff20dc8476293e56f5a60be3c3ex358x255.JPEG\" alt=\"Explanation Image\"><p>Option C: Integrated Child Development Services (ICDS)</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/6947bfa0b6be4b85aed17fd762622596x720x697.PNG\" alt=\"Explanation Image\"><p>Option D:&nbsp;National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Disease, and Stroke (NPCDCS).</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e44d8eb29f574ef7aaf9f55d5e89f374x406x319.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/5ecaf237f12d4ce098a376efa930b680.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7951",
      "difficulty": "easy"
    },
    {
      "text": "The following drug packet is used in:",
      "choices": [
        {
          "id": 1,
          "text": "TB"
        },
        {
          "id": 2,
          "text": "Leprosy"
        },
        {
          "id": 3,
          "text": "Vaginal discharge"
        },
        {
          "id": 4,
          "text": "Gonorrhea"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given image shows the adult blister packet used in the treatment of&nbsp;<strong>leprosy.</strong></p><hr><h3>Related Pearl: WHO proposed Multi Drug Therapy (MDT) for the treatment of Leprosy</h3><p><strong>WHO proposed Multi-Drug Therapy (MDT) for the treatment of Leprosy</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Age group</strong></p>\n</td>\n<td>\n<p><strong>Drug</strong></p>\n</td>\n<td>\n<p><strong>Duration of Treatment</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adult</p>\n</td>\n<td>\n<p><strong>Rifampicin 600 mg</strong> once a month</p>\n<p>+</p>\n<p><strong>Clofazimine 300 mg</strong> once a month and <strong>50 mg daily</strong></p>\n<p>+</p>\n<p><strong>Dapsone 100 mg</strong> daily</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children (10&ndash;14 years)</p>\n</td>\n<td>\n<p>Rifampicin <strong>450 mg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>150 mg</strong> once a month and 50 mg <strong>alternate days</strong>.</p>\n<p>+</p>\n<p>Dapsone <strong>50 mg</strong> daily&nbsp;</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>\n</td>\n<td>&nbsp;\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children &lt;10 years old or &lt;40 kg</p>\n</td>\n<td>\n<p>Rifampicin <strong>10 mg/kg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>100mg</strong> once a month, 50mg <strong>twice weekly</strong></p>\n<p>+</p>\n<p>Dapsone <strong>2 mg/kg</strong> daily</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b1f7454268d74e0ebae486cbcdea6ee5.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7004",
      "difficulty": "easy"
    },
    {
      "text": "The Sparsh campaign was launched to spread awareness about which of the following diseases?",
      "choices": [
        {
          "id": 1,
          "text": "HIV"
        },
        {
          "id": 2,
          "text": "Immunization"
        },
        {
          "id": 3,
          "text": "Leprosy"
        },
        {
          "id": 4,
          "text": "TB"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Sparsh Leprosy Awareness Campaign</strong>&nbsp;(SLAC) was introduced in 2017 on the occasion of the anti-leprosy day (observed on the last Sunday of January) to promote awareness about various aspects of leprosy.</p>\n<p><strong>Sapna</strong>&nbsp;refers to a local school-going girl who will help to spread awareness in the community.</p>\n<p>The other <strong>developments </strong>under<strong> NLEP </strong>are:</p>\n<ul>\n<li><strong>Mycobacterium Indicus Prani&nbsp;(MiP)</strong> <strong>vaccine</strong>&nbsp;for multibacillary leprosy patients and their contacts (it is in a project mode).</li>\n<li><strong>Nikusth: </strong>A web-based system for the data management of leprosy cases.</li>\n</ul>\n<p><strong>Note</strong>: <strong>Meena</strong> is a nine-year-old girl, who is the symbol of <strong>UNICEF's</strong> Girl Empowerment programme to impart&nbsp;important messages on gender, child rights, education, health and development in the South Asian region.</p>\n<p>The posters below depict the role play by <strong>Sapna</strong>:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3c3f3fd64065464892abdd6ae9e7e1d1x966x524.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2535",
      "difficulty": "easy"
    },
    {
      "text": "A patient with leprosy comes to the PHC following a pinprick to his foot. He noticed it only after seeing bloodstains on the floor and complains of loss of sensation in his foot. After addressing the issue, the patient is referred to another centre. Where has he been referred to and why?",
      "choices": [
        {
          "id": 1,
          "text": "For secondary prevention to a district hospital."
        },
        {
          "id": 2,
          "text": "For tertiary prevention to a district hospital."
        },
        {
          "id": 3,
          "text": "For secondary prevention to a district nucleus."
        },
        {
          "id": 4,
          "text": "For tertiary prevention to a district nucleus."
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario of a patient with leprosy having <strong>neuropathy</strong> needs <strong>Micro Cellular Rubber (MCR) footwear</strong>, which is a form of <strong>tertiary</strong> <strong>prevention</strong>. He is to be referred to a <strong>district</strong>&nbsp;<strong>nucleus</strong> which supplies MCR footwear to patients.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/9e295da1bf594a7e9d1e226e9d6a8c0cx1280x2560.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4587",
      "difficulty": "hard"
    },
    {
      "text": "A patient with leprosy, who has completed a course of multi-drug therapy, presents with complaints of developing painful, tender, and raised lesions on his forehead recently as shown in the image below. What is the first-line treatment for him?",
      "choices": [
        {
          "id": 1,
          "text": "Restart multi drug therapy and start thalidomide"
        },
        {
          "id": 2,
          "text": "Restart multi drug therapy and start prednisolone"
        },
        {
          "id": 3,
          "text": "Start on clofazimine only"
        },
        {
          "id": 4,
          "text": "Start on prednisolone only"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The presence of <strong>new</strong> <strong>erythematous</strong> and <strong>tender</strong> subcutaneous <strong>nodules</strong> in a patient with leprosy indicates that he has developed <strong>type II lepra reaction. </strong>It is also known as <strong>Erythema Nodosum Leprosum (ENL) </strong>and the first line of treatment is <strong>prednisolone</strong>.</p>\n<p>Multi-drug therapy <strong>(MDT) should not be restarted</strong> in patients who develop lepra reactions after the completion of treatment.</p>\n<p>Prednisolone is started at a dose of 40 mg per day and gradually tapered by 5 mg every 2 weeks. 'Prednisolone card' is given when treatment is started. If the patient becomes <strong>steroid-dependent</strong>, then <strong>clofazimine</strong> is added.</p>\n<p>The <strong> key targets</strong> of the Global Leprosy Strategy <strong>2021-2023</strong> announced by WHO (Accelerating towards a leprosy-free world) are:</p>\n<ul>\n<li>120 countries reporting zero new autochthonous cases.</li>\n<li>70% reduction in the annual number of new cases detected.</li>\n<li>90% reduction in rate per million population of new cases with Grade 2 disability.</li>\n<li>90% reduction in rate per million children of new child cases with leprosy.</li>\n</ul>\n<p>The current goal is the elimination of leprosy. </p><hr><h3>Related Pearl: Lepra Reactions</h3><p><strong>Lepra Reactions:</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type 1 Reaction</strong></p>\n<p>(Reversal/Upgrading)</p>\n</td>\n<td>\n<p><strong>Type 2 Reaction</strong></p>\n<p>(Erythema Nodosum Leprosum)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Mainly seen in the&nbsp;<strong>Borderline</strong> spectrum (BT, BB, BL)</p>\n<p><strong>Most severe</strong> in Borderline Lepromatous(BL) leprosy</p>\n</td>\n<td>Mainly seen in <strong>LL</strong>(50%)&gt;BL(15%)</td>\n</tr>\n<tr>\n<td>\n<p>Usually seen <strong>within 12 months</strong> of initiation of Multidrug Therapy</p>\n</td>\n<td><strong>Unrelated</strong> to Multidrug therapy. May occur before, during or after treatment</td>\n</tr>\n<tr>\n<td>\n<p><strong>Type 4</strong> Hypersensitivity</p>\n<p>Due to <strong>enhanced cell-mediated response</strong>&nbsp;increased destruction of bacilli following treatment in reversal</p>\n</td>\n<td>\n<p><strong>Type 3</strong> Hypersensitivity</p>\n<p>Primarily Humoral</p>\n<p>(<strong>Immune complex Deposition</strong> in tissues and vessels)</p>\n<p>Cytokine involved - <strong>TNF-&alpha;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inflammation of <strong>existing skin lesions</strong> (red, painful edematous skin lesions) that may <strong>ulcerate</strong></p>\n<p>New lesions may occur (rare)</p>\n<p><strong>Neuritis</strong>&nbsp;and <strong>Nerve abscesses&nbsp;</strong>(red, painful inflamed nerves)</p>\n</td>\n<td>\n<p><strong>New, erythematous and tender</strong>, subcutaneous and dermal nodules that are widely distributed over extremities and face</p>\n<p>Existing lesions do not change</p>\n</td>\n</tr>\n<tr>\n<td><strong>No</strong> systemic involvement</td>\n<td><strong>Systemic symptoms</strong> present - fever, myalgias, arthralgias, anorexia, keratitis, iritis, nephritis, synovitis, orchitis, lymphadenopathy</td>\n</tr>\n<tr>\n<td>\n<p><strong>Treatment:</strong></p>\n<p>Supportive therapy for mild reactions with <strong>NSAIDs</strong></p>\n<p>In case of severe reactions with neuritis and eye lesions- <strong>Oral corticosteroids</strong></p>\n<p><strong>(Drug of Choice)</strong></p>\n<p>Nerve Abscess - Additional <strong>surgical drainage</strong></p>\n<p>Other drugs: Clofazimine, Cyclosporine</p>\n</td>\n<td>\n<p><strong>Treatment:</strong></p>\n<p><strong>Oral Corticosteroids - First-line drug<br /><br />Clofazimine </strong>(Steroid dependent ENL)<strong><br /></strong></p>\n<p><strong>Thalidomide -most effective </strong>but not used first due to various side effects</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/72150c3fc1eb478f82fd07f89f059d6f.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4591",
      "difficulty": "medium"
    },
    {
      "text": "ABSULS, which is an ASHA-based surveillance project, has been initiated for which of the following diseases?",
      "choices": [
        {
          "id": 1,
          "text": "Leishmaniasis"
        },
        {
          "id": 2,
          "text": "Diarrhoeal diseases"
        },
        {
          "id": 3,
          "text": "Leprosy"
        },
        {
          "id": 4,
          "text": "Sexually Transmitted Diseases (STDs)"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>ABSULS</strong>&nbsp;which stands for&nbsp;<strong>Asha Based Surveillance for Leprosy Suspects&nbsp;</strong>has been initiated to prioritize leprosy case detection by ASHAs.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3609",
      "difficulty": "easy"
    },
    {
      "text": "The treatment of paucibacillary leprosy consists of MDT (which comprises rifampicin, dapsone, and clofazimine). The latest recommended regimen is:",
      "choices": [
        {
          "id": 1,
          "text": "2 drug therapy for 6 months"
        },
        {
          "id": 2,
          "text": "3 drug therapy for 12 months"
        },
        {
          "id": 3,
          "text": "2 drug therapy for 12 months"
        },
        {
          "id": 4,
          "text": "3 drug therapy for 6 months"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>latest recommendation </strong>is <strong>3 drug </strong>therapy for <strong>6 months</strong> to treat <strong>paucibacillary</strong> (PB)<strong> </strong>leprosy by <strong>WHO. </strong>The regimen consists of rifampicin, dapsone, and clofazimine.</p>\n<p>Meanwhile,<strong> multibacillary </strong>(MB)<strong> </strong>leprosy is treated using the same <strong>3 drugs</strong> for a duration of <strong>12 months. </strong>While the NLEP guidelines earlier mentioned a 2-drug MDT for PB leprosy, the <strong>National Strategic Plan and Roadmap for Leprosy (2023-2027)</strong> now recommends a <strong>uniform MDT of 3 drugs</strong> for both PB and MB leprosy.</p>\n<p><strong>Note:</strong> The central government has approved a new treatment regimen for paucibacillary (PB) leprosy. The Ministry of Health and Family Welfare has introduced a 3-drug regimen for PB leprosy instead of a 2-drug regimen. This revised drug regimen will be applicable in India from April 1, 2025.</p><hr><h3>Related Pearl: WHO proposed Multi Drug Therapy (MDT) for the treatment of Leprosy</h3><p><strong>WHO proposed Multi-Drug Therapy (MDT) for the treatment of Leprosy</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Age group</strong></p>\n</td>\n<td>\n<p><strong>Drug</strong></p>\n</td>\n<td>\n<p><strong>Duration of Treatment</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adult</p>\n</td>\n<td>\n<p><strong>Rifampicin 600 mg</strong> once a month</p>\n<p>+</p>\n<p><strong>Clofazimine 300 mg</strong> once a month and <strong>50 mg daily</strong></p>\n<p>+</p>\n<p><strong>Dapsone 100 mg</strong> daily</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children (10&ndash;14 years)</p>\n</td>\n<td>\n<p>Rifampicin <strong>450 mg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>150 mg</strong> once a month and 50 mg <strong>alternate days</strong>.</p>\n<p>+</p>\n<p>Dapsone <strong>50 mg</strong> daily&nbsp;</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>\n</td>\n<td>&nbsp;\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Children &lt;10 years old or &lt;40 kg</p>\n</td>\n<td>\n<p>Rifampicin <strong>10 mg/kg</strong> once a month</p>\n<p>+</p>\n<p>Clofazimine <strong>100mg</strong> once a month, 50mg <strong>twice weekly</strong></p>\n<p>+</p>\n<p>Dapsone <strong>2 mg/kg</strong> daily</p>\n</td>\n<td>\n<p>12 months (MB)</p>\n<p>6 months (PB)</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0183",
      "difficulty": "medium"
    },
    {
      "text": "A District Leprosy Officer is preparing the annual report as per NLEP 2020. Which of the following parameters would he not consider as an essential indicator?",
      "choices": [
        {
          "id": 1,
          "text": "Treatment Completion Rate (TCR)"
        },
        {
          "id": 2,
          "text": "Prevalence rate (PR)"
        },
        {
          "id": 3,
          "text": "Rate of new cases with Grade II disabilities per 10 lakh population per year"
        },
        {
          "id": 4,
          "text": "Proportion of new cases correctly diagnosed"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The proportion of new cases correctly diagnosed is not included under essential indicators. It is a part of the quality of service indicators as per NLEP 2020.&nbsp;</p>\n<p>The <strong>essential indicators</strong> include:</p>\n<ul>\n<li>Annual new case detection rate (<strong>ANCDR</strong>) per 1 lakh population.</li>\n<li>Rate of new cases with grade II disabilities (<strong>G2D</strong>) per 10 lakh population per year.</li>\n<li>Treatment completion rate (<strong>TCR</strong>) as a proxy to cure rate.</li>\n<li>Prevalence rate (<strong>PR</strong>).</li>\n</ul>\n<p><strong>Additional epidemiological indicators</strong> include:</p>\n<ul>\n<li>Proportion of Grade II disabilities among new cases.</li>\n<li>Proportion of females among new cases.&nbsp;</li>\n<li>Proportion of multibacillary (MB) among new cases.</li>\n<li>Proportion of child (0- 14 years) among new cases.&nbsp;</li>\n<li>Child rate per 100,000 population.&nbsp;</li>\n<li>Scheduled Caste New Case Detection Rate.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7238",
      "difficulty": "medium"
    },
    {
      "text": "As per NLEP 2020, which of the following is not a quality of service indicator?",
      "choices": [
        {
          "id": 1,
          "text": "Patient month blister calendar pack stock"
        },
        {
          "id": 2,
          "text": "Proportion of grade II disabilities among new cases."
        },
        {
          "id": 3,
          "text": "Number of relapses reported"
        },
        {
          "id": 4,
          "text": "Proportion of cases who developed new or additional disability after starting  MDT"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Proportion of grade II disabilities among new cases</strong> is not a quality of service indicator. It is an <strong>additional epidemiological indicator</strong> as per NLEP 2020.</p>\n<p>The <strong>quality of service indicators</strong> are:&nbsp;</p>\n<ul>\n<li>Patient month blister calendar pack stock.&nbsp;</li>\n<li>Absolute number of patients made released from treatment (RFT).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>\n<li>Number of relapse reported.&nbsp;</li>\n<li>Proportion of cases who developed new or additional disability after starting MDT.&nbsp;</li>\n<li>Proportion of treatment defaulters.</li>\n<li>Proportion of new cases correctly diagnosed.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7239",
      "difficulty": "medium"
    },
    {
      "text": "You are part of a rural health camp organized under Project Axshya. Which of the following diseases does it aim to control?",
      "choices": [
        {
          "id": 1,
          "text": "Diabetes"
        },
        {
          "id": 2,
          "text": "Kala azar"
        },
        {
          "id": 3,
          "text": "Tuberculosis"
        },
        {
          "id": 4,
          "text": "Zika Virus disease"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Project <strong>Axshya</strong> was launched in 2010 to control <strong>TB</strong>. Axshya means<strong> free from TB</strong> which is the ultimate goal of the project and the National TB Elimination Programme.</p>\n<p>Project Axshya is being implemented by the International Union Against Tuberculosis and Lung Disease (known simply as The Union). The project works to improve access to quality TB care and control through a partnership between the government and civil society.</p>\n<p>The guiding principles of project Axshya are:</p>\n<ul>\n<li>Universal access to quality TB services</li>\n<li>Community participation in TB care and control</li>\n<li>Sustainable interventions and equitable distribution of project benefits with social and gender sensitivity</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6809",
      "difficulty": "medium"
    },
    {
      "text": "You are working as a medical officer in a PHC where you diagnose a patient with TB. Within how many days do you have to report it to the District Health Officer?",
      "choices": [
        {
          "id": 1,
          "text": "7 days"
        },
        {
          "id": 2,
          "text": "15 days"
        },
        {
          "id": 3,
          "text": "30 days"
        },
        {
          "id": 4,
          "text": "21 days"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The guidelines for TB notification under the RNTCP is within <strong>30 days</strong> (a month) of receiving a new case. The notification must be done to the <strong>District Health Officer</strong> or the Chief Medical Officer of a District Hospital by the&nbsp;practitioner who diagnosed it.</p>\n<p>Note: RNTCP has now been renamed to National Tuberculosis Elimination Program (<strong>NTEP</strong>).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7964",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is true about the Revised National Tuberculosis Control Programme?",
      "choices": [
        {
          "id": 1,
          "text": "Follow-up sputum smear examination at the end of intensive phase only"
        },
        {
          "id": 2,
          "text": "Directly Observed Treatment Short course strategy is applied"
        },
        {
          "id": 3,
          "text": "Treatment is only given to smear positive cases"
        },
        {
          "id": 4,
          "text": "MDR TB is resistance to either rifampicin or isoniazid"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>DOTS stands for&nbsp;<strong>Directly Observed Treatment Short-course</strong> and is&nbsp;given by peripheral and voluntary health workers.</p>\n<p><strong>Recent updates in RNTCP:</strong></p>\n<ul>\n<li><strong>Active case finding</strong> for TB has been started.</li>\n<li><strong>Follow up:&nbsp;</strong>\n<ul>\n<li>On treatment: <strong>monthly </strong>follow up.<strong>&nbsp;</strong></li>\n<li>After treatment: Follow up at 6, 12, 18 and 24 months.</li>\n<li>A sputum smear examination must be done at the<strong> end of</strong> intensive phase (<strong>IP</strong>) <strong>and</strong> at the <strong>end of treatment</strong>.</li>\n</ul>\n</li>\n</ul><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p><hr><h3>Related Pearl: Classification of TB Patients Based on History of Treatment</h3><p><strong>New case</strong> is defined as a TB patient who had</p>\n<ul>\n<li><strong>Never taken</strong> ATT previously or</li>\n<li>Taken ATT for <strong>&lt; 1 month</strong></li>\n</ul>\n<p><strong>Previously treated Case :&nbsp;</strong>Patients who have <strong>received 1 month or more</strong> of Anti TB drugs in the past. These include:</p>\n<ol>\n<li><strong>Recurrent TB:&nbsp;</strong>A TB patient who <strong>had completed course of treatment</strong> <strong>/ declared cured</strong> and now presenting as microbiologically confirmed case</li>\n<li><strong>Treatment after failure:&nbsp;</strong>Patients who had been treated for TB and <strong>their treatment failed</strong> at the end of most recent course of treatment</li>\n<li><strong>Treatment after loss to follow up:&nbsp;</strong>A TB patient who had <strong>been treated &gt; 1 month on ATT</strong> and registered as l<strong>ost to follow up</strong> and now presenting as microbiologically confirmed case of TB</li>\n<li><strong>Other previously treated patients:&nbsp;</strong>Patients who had been previously treated but whose <strong>outcome is now unknown/undocumented</strong></li>\n</ol>\n<p><strong>Transferred in:&nbsp;</strong>A TB patient who has been received in a TB unit after having registered in another TB unit for treatment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7958",
      "difficulty": "medium"
    },
    {
      "text": "A patient presents with fever, productive cough, and weight loss. He gives a history of not having completed treatment for tuberculosis thrice in the past. Extensively drug-resistant TB is suspected. How is this entity defined?",
      "choices": [
        {
          "id": 1,
          "text": "Resistance to INH + Amikacin + Ofloxacin + Ethambutol"
        },
        {
          "id": 2,
          "text": "Resistance to INH + Rifampicin + Amikacin"
        },
        {
          "id": 3,
          "text": "Resistance to Rifampicin + Amikacin+ Ofloxacin"
        },
        {
          "id": 4,
          "text": "Resistance to INH + Rifampicin + Ofloxacin + Linezolid"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong> XDR-TB</strong> (<strong>extensively drug-resistant&nbsp;TB</strong>) is defined as <strong>multi-drug resistant&nbsp; TB</strong> (resistant to rifampicin and isoniazid) which is also<strong>&nbsp;</strong>resistant to one <strong>fluoroquinolone</strong> (eg. ofloxacin) AND&nbsp;resistant to atleast one additional group A drug (as of 2021, these are&nbsp;<a href=\"https://www.uptodate.com/contents/bedaquiline-drug-information?search=xdr+tb&amp;topicRef=8028&amp;source=see_link\" target=\"_blank\" rel=\"noopener\" data-topicid=\"87509\">bedaquiline</a>&nbsp;and&nbsp;<a href=\"https://www.uptodate.com/contents/linezolid-drug-information?search=xdr+tb&amp;topicRef=8028&amp;source=see_link\" target=\"_blank\" rel=\"noopener\" data-topicid=\"10283\">linezolid)</a></p>\n<p>It is usually seen in patients who have previously received treatment for TB and have either failed to complete treatment or relapsed.</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF6030",
      "difficulty": "easy"
    },
    {
      "text": "A patient on HAART presents with complaints of fever and expectorant cough for two weeks. What is the investigation to be ordered first?",
      "choices": [
        {
          "id": 1,
          "text": "Sputum microscopy"
        },
        {
          "id": 2,
          "text": "Interferon Gamma Release Assay"
        },
        {
          "id": 3,
          "text": "CB- NAAT"
        },
        {
          "id": 4,
          "text": "Sputum microscopy and Chest X-ray"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>An <strong>HIV</strong> patient <strong>suspected</strong> to have <strong>TB</strong> is directly investigated by <strong>CB-NAAT</strong> (Cartridge Based Nucleic Acid Amplification Test).</p>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;This is recent update in PSM. TB is a very serious infection in the immunocompromised and can lead to its most severe form as Miliary TB and lead to death of the patient. Since TB in HIV doesn't have its typical presentation, early suspicion and advanced diagnosis is the key to prevent mortality.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:769,&quot;3&quot;:[null,0],&quot;11&quot;:4,&quot;12&quot;:0}\">TB is a very serious infection in the immunocompromised and can lead to its most severe form as <strong>miliary TB</strong> and cause death. Since TB in HIV does not have its typical presentation, early suspicion and advanced diagnosis is the key to preventing mortality.</span></p>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;This is recent update in PSM. TB is a very serious infection in the immunocompromised and can lead to its most severe form as Miliary TB and lead to death of the patient. Since TB in HIV doesn't have its typical presentation, early suspicion and advanced diagnosis is the key to prevent mortality.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:769,&quot;3&quot;:[null,0],&quot;11&quot;:4,&quot;12&quot;:0}\">Diagnostic algorithm for TB:</span></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ca905a544a0e457bb001e3ece1387935x1280x2207.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Diagnostic algorithm for Pulmonary TB – National Tuberculosis Elimination Programme (NTEP) 2020 Guidelines</h3><p>Any case of&nbsp;<strong>presumptive pulmonary TB</strong>&nbsp;should undergo <strong>sputum examination + chest X-ray + CB-NAAT</strong></p>\n<ul>\n<li>If sputum and chest X-ray normal:<strong> rule out TB and refer</strong></li>\n<li>If sputum is positive and CB NAAT is positive:<strong>&nbsp;microbiologically confirmed case of TB</strong></li>\n</ul>\n<p>The following protocol is used for <strong>CB-NAAT testing:</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e8d17e5087654b588b4b519b350acb71x1280x2558.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4774",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements is false under the National Tuberculosis Elimination Programme?",
      "choices": [
        {
          "id": 1,
          "text": "Continuation phase for new sputum smear positive: HRE for 16 weeks"
        },
        {
          "id": 2,
          "text": "Intensive phase for sputum smear positive after loss to follow up: HRZE for 8 weeks"
        },
        {
          "id": 3,
          "text": "Continuation phase for sputum smear positive recurrent case: HRE for 16 weeks"
        },
        {
          "id": 4,
          "text": "Intensive phase for sputum smear positive after failure to treatment: HRZES for 12 weeks"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Under National Tuberculosis Elimination Programme (NTEP) guidelines <strong>Initiation phase</strong> (IP) for <strong>both new and previously treated</strong> cases which are H and R sensitive is <strong>HRZE </strong>for<strong> 8 weeks</strong>.</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA3569",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most peripheral centre under the Revised National Tuberculosis Control Programme organization structure?",
      "choices": [
        {
          "id": 1,
          "text": "District TB centre"
        },
        {
          "id": 2,
          "text": "Intermediate Reference Laboratory"
        },
        {
          "id": 3,
          "text": "Tuberculosis Unit"
        },
        {
          "id": 4,
          "text": "Designated Microscopy Centre"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Among the options given, <strong>Designated Microscopy Centre</strong> is the most peripheral centre.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/cc45443a1d044860a9be5b4cb6edf627x783x885.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4189",
      "difficulty": "medium"
    },
    {
      "text": "Which is the new online software launched under the national tuberculosis elimination program (NTEP) by the government to monitor TB patients?",
      "choices": [
        {
          "id": 1,
          "text": "NIKSHAY"
        },
        {
          "id": 2,
          "text": "NISCHAY"
        },
        {
          "id": 3,
          "text": "E-DOTS"
        },
        {
          "id": 4,
          "text": "NIKUSTH"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Nikshay </strong>is the new online software launched under the national tuberculosis elimination program for monitoring <strong>TB</strong> patients.</p>\n<p><strong>Nikusth</strong> is the new online software for monitoring <strong>leprosy </strong>patients.</p>\n<p><strong>Nischay</strong> is a <strong>pregnancy</strong> test kit.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9550",
      "difficulty": "easy"
    },
    {
      "text": "Choose the false statement regarding the initiatives and strategies for tuberculosis.",
      "choices": [
        {
          "id": 1,
          "text": "The Stop TB strategy was announced by the World Health Organisation"
        },
        {
          "id": 2,
          "text": "The STOP TB strategy has a target of ending TB by achieving an  incidence rate of <10 people per 10,000 population per year"
        },
        {
          "id": 3,
          "text": "The \"Practical approach to lung health\" was launched by the WHO for syndromic managment of patients with respiratory symptoms"
        },
        {
          "id": 4,
          "text": "The End TB strategy is a 20 year programme"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>Stop TB</strong> strategy was announced by World Health Organisation to <strong>reduce</strong> the global burden of TB by 2015 (and not ending TB).&nbsp;</p>\n<p>The<strong>&nbsp;End TB</strong>&nbsp;strategy is a <strong>20-year</strong> programme with&nbsp;tagline &ldquo;A world free of TB - Zero TB deaths, Zero TB disease, and Zero TB suffering&rdquo;. It aims to:</p>\n<ul>\n<li>end TB by achieving an incidence rate of <strong>&lt;10 people/1 lakh population per year&nbsp;by 2035.&nbsp;</strong></li>\n<li>reduce TB <strong>deaths by 95%</strong> and cut <strong>new cases by 90%</strong> by 2035.</li>\n</ul>\n<p>&nbsp;The \"<strong>Practical approach to lung health initiative</strong>\" was launched by the <strong>WHO</strong> as a <strong>syndromic approach</strong> to the management of patients who attend primary health care services for respiratory symptoms.</p>\n<p>Ending the TB epidemic is also one of the targets of the Sustainable Development Goals (SDG) specifically under Goal 3 (to &ldquo;ensure healthy lives and promote well-being for all at all ages&rdquo;).</p><table>\n<tbody>\n<tr>\n<td colspan=\"3\"><strong>Vision of End TB</strong>: A world free of TB- zero deaths, disease and suffering due to TB</td>\n</tr>\n<tr>\n<td colspan=\"3\"><strong>Goal</strong>: End the global TB epidemic</td>\n</tr>\n<tr>\n<td><strong>Indicators</strong></td>\n<td colspan=\"2\"><strong>Targets</strong></td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td><strong>SDG 2030</strong></td>\n<td><strong>End TB 2035</strong></td>\n</tr>\n<tr>\n<td>Reduction in no. of TB deaths compared with 2015</td>\n<td>90%</td>\n<td>95%</td>\n</tr>\n<tr>\n<td>Reduction in TB incidence rate compared with 2015</td>\n<td>\n<p>80%</p>\n<p>(&lt;20/1,00,000)</p>\n</td>\n<td>\n<p>90%</p>\n<p>(&lt;10/1,00,000)</p>\n</td>\n</tr>\n<tr>\n<td>TB-affected families facing catastrophic costs due to TB</td>\n<td>0%</td>\n<td>0%</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>WHO defines that \"<strong>Tuberculosis control</strong>\" would be achieved when the <strong>prevalence</strong> of the natural order of infection in the age group of <strong>0-14 years</strong> is of the <strong>order of 1%</strong> (40% in India currently).</p><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;World TB Day is observed annually on March 24 to raise awareness about TB and efforts to end the global epidemic, marking the day in 1882 when the bacterium causing TB was discovered. This year's theme is 'Yes! We can end TB!', aims to inspire hope and encourage faster uptake of new WHO recommendations, adoption of innovations, accelerated action, and multisectoral collaboration to combat the TB epidemic&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\"><strong>World TB Day</strong> is observed annually on <strong>March 24</strong> to raise awareness about TB and efforts to end the global epidemic, marking the day in 1882 when the bacterium causing TB was discovered. This year's theme is <strong>'Yes! We can end TB!'</strong>, aims to inspire hope and encourage faster uptake of new WHO recommendations, adoption of innovations, accelerated action, and multisectoral collaboration to combat the TB epidemic</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3581",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following group of individuals would you not target under the programme represented by the logo shown below?",
      "choices": [
        {
          "id": 1,
          "text": "Sex workers"
        },
        {
          "id": 2,
          "text": "Migrants"
        },
        {
          "id": 3,
          "text": "Transgenders"
        },
        {
          "id": 4,
          "text": "Industrial workers"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>red ribbon&nbsp;</strong>shown is a part of the logo of the&nbsp;<strong>National AIDS Control Organization (NACO) programme.&nbsp;</strong>Industrial workers are not included in the target population under NACO.</p>\n<p><strong>Target interventions</strong>&nbsp;for the control of AIDS transmission are done for:</p>\n<ul>\n<li>High-risk groups like <strong>sex workers</strong></li>\n<li><strong>Men who have sex with men</strong></li>\n<li><strong>Transgender</strong></li>\n<li>Injecting drug users</li>\n<li><strong>Bridge population</strong> like migrants and long-distance truckers</li>\n</ul>\n<p>The services offered through targeted interventions include <strong>detection</strong> and <strong>treatment</strong> for sexually transmitted diseases and condom distribution.</p>\n<p>The <strong>logo</strong> of NACO:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d584cf3d81344b64a0fcb59696537670x537x245.PNG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/5d95baebd5bd4af69a3fa855a1012849.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7968",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is false regarding the target interventions under National AIDS Control Organisation?",
      "choices": [
        {
          "id": 1,
          "text": "Lubricants are given to  homosexual men"
        },
        {
          "id": 2,
          "text": "Clean needles and syringes are given to injecting drug users"
        },
        {
          "id": 3,
          "text": "Condoms are not given to bridge population"
        },
        {
          "id": 4,
          "text": "Opioid substitution therapy is given to Injecting Drug Users"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Bridge populations <strong>are supplied with condoms</strong> under the NACO target interventions. </p>\n<p><strong>Target interventions: </strong></p>\n<p>General:</p>\n<ul>\n<li>Detection and treatment for sexually transmitted diseases</li>\n<li>Condom distribution</li>\n</ul>\n<p><strong>For injecting drug users:</strong></p>\n<ul>\n<li><strong>Distribution of clean needles and syringes.</strong></li>\n<li>Abscess prevention and management.</li>\n<li>Opioid substitution therapy.</li>\n<li>Linkage with detoxification and rehabilitation services.</li>\n</ul>\n<p><strong>For homosexual men and transgenders:</strong></p>\n<ul>\n<li>Provision of lubricants.</li>\n<li>Provision of project-based clinics for sexually transmitted infections.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4620",
      "difficulty": "medium"
    },
    {
      "text": "A physician follows the two test protocol for the diagnosis of HIV in a patient. It consists of:",
      "choices": [
        {
          "id": 1,
          "text": "Western blot as the first test"
        },
        {
          "id": 2,
          "text": "Line immunoassay as the second test"
        },
        {
          "id": 3,
          "text": "HIV ELISA as the second test"
        },
        {
          "id": 4,
          "text": "Western blot  as the second test"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>two test protocol</strong> for the diagnosis of HIV consists of <strong>ELISA as the second test</strong>. If the initial ELISA is positive, a second ELISA is carried out. If the <strong>second ELISA</strong> is also <strong>positive</strong>, only then the <strong>case</strong> is reported to be <strong>positive</strong>.</p>\n<p>Investigations involved in HIV testing strategies:</p>\n<ol>\n<li>ELISA/ rapid tests.</li>\n<li>Confirmatory tests with high specificity like <strong>western blot</strong> and <strong>line immunoassays</strong> are used in problem cases eg: indeterminate/ discordant cases of rapid tests.</li>\n</ol>\n<p>In India, NACO provides <strong>western blot </strong>(WB) confirmatory testing <strong>only to resolve indeterminate results</strong> on previous serological testing. It is <strong>not </strong>used <strong>for routine confirmation</strong> after a positive result on screening tests. Drawbacks of WB include low rates of detection during<strong> acute HIV</strong> infection and <strong>misclassification of HIV-2 </strong>infection.</p>\n<p><strong>Note</strong>: The western blot is used as a confirmatory test after 2 indeterminate primary tests (ELISA). It is essentially the third test used and does not fit into the two test protocol.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4592",
      "difficulty": "hard"
    },
    {
      "text": "As a medical officer involved in the sentinel surveillance for HIV under the National AIDS Control Programme, your duties include all of the following except:",
      "choices": [
        {
          "id": 1,
          "text": "Estimation of total infection in the community"
        },
        {
          "id": 2,
          "text": "Estimation of total cases in hospitals"
        },
        {
          "id": 3,
          "text": "Estimation of trend of disease"
        },
        {
          "id": 4,
          "text": "Classification of districts"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>As a medical officer involved in the sentinel surveillance, the <strong>estimation of total cases</strong> in hospitals is <strong>not included</strong> in the sentinel surveillance for HIV under National AIDS Control Programme (NACO).</p>\n<p>The aims of the <strong>HIV sentinel surveillance</strong> include:</p>\n<ul>\n<li>Determine the level of HIV infection in the community.</li>\n<li>Understand the trends of HIV epidemic.</li>\n<li>Understand the geographical spread of HIV infection and classify districts according to epidemiological and vulnerability criteria.</li>\n</ul>\n<p>These objectives are achieved by conducting <strong>annual cross-sectional surveys</strong> of the risk group in the same geographical place.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7970",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is targetted by the establishment bearing the logo shown below:",
      "choices": [
        {
          "id": 1,
          "text": "Family planning"
        },
        {
          "id": 2,
          "text": "Immunisation"
        },
        {
          "id": 3,
          "text": "Sexually Transmitted Diseases"
        },
        {
          "id": 4,
          "text": "Maternal and Child Health Services"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The logo shown represents <strong>Suraksha Clinics </strong>which are established for the management of <strong>sexually transmitted diseases</strong> (STDs) where patients are given color-coded kits.</p><hr><h3>Related Pearl: Syndromic Management of Sexually Transmitted Infections</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1167210a9cd6434a905a98bc64668d41x1280x2612.PNG\" alt=\"Pearl Image\"><p>Partner Management when <strong>asymptomatic</strong> is not required for <strong>Gardenella vaginalis, Candida and Herpes infections</strong>.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/60da7b1257d04ca5938ef3340533e6b9x1280x2974.JPEG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/1d69affdd5634762b14708fd5335a989.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7973",
      "difficulty": "easy"
    },
    {
      "text": "Choose the wrong combination of the colour-coded STI kits among the given options.",
      "choices": [
        {
          "id": 1,
          "text": "Kit 6 – yellow"
        },
        {
          "id": 2,
          "text": "Kit 3 – white"
        },
        {
          "id": 3,
          "text": "Kit 4 – black"
        },
        {
          "id": 4,
          "text": "Kit 5 – red"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Kit</strong> <strong>4</strong> is <strong>blue</strong>&nbsp;in colour and is used for genital ulcers.&nbsp;These kits are given at Suraksha clinics.</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: Syndromic Management of Sexually Transmitted Infections</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1167210a9cd6434a905a98bc64668d41x1280x2612.PNG\" alt=\"Pearl Image\"><p>Partner Management when <strong>asymptomatic</strong> is not required for <strong>Gardenella vaginalis, Candida and Herpes infections</strong>.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/60da7b1257d04ca5938ef3340533e6b9x1280x2974.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7975",
      "difficulty": "easy"
    }
  ]
}